MAPT and early-onset autosomal dominant Alzheimer disease: Limitations of this work include the following: The results obtained in mice (association between the NFTs in EC and path integration) need to be further verified and validated in humans (e.g. association between individual path integration declines and Alzheimer’s disease biomarkers, tau PET, MRI).